Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

argenx SE

Healthcare US ARGNF

835.0USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

803.19803.19
LowHigh

52 Week Range

532.40872.27
LowHigh

Fundamentals

  • Previous Close 835.00
  • Market Cap58619.17M
  • Volume1
  • P/E Ratio45.77
  • Dividend Yield-%
  • EBITDA1061.90M
  • Revenue TTM4236.47M
  • Revenue Per Share TTM69.12
  • Gross Profit TTM 2421.67M
  • Diluted EPS TTM19.55

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1278.61M 85.18M -304.49600M -729.31400M -399.74300M
Minority interest - - - - -
Net income 1292.04M 833.04M -295.05300M -709.59400M -408.26500M
Selling general administrative 1359.98M 1052.19M 709.54M 472.13M 307.64M
Selling and marketing expenses - - - - -
Gross profit 3702.82M 1962.94M 1108.48M 381.31M -
Reconciled depreciation 28.10M 17.53M 111.31M 104.34M 5.87M
Ebit - - - -723.91800M -359.89800M
Ebitda - - - -725.40800M -354.03100M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 1054.62M -17.84400M -420.63800M -719.66300M -359.89800M
Other operating expenses - - - - 17.02M
Interest expense 4.08M 2.46M 0.91M 3.91M 1.10M
Tax provision -13.42800M -747.86000M -9.44300M -19.72000M 8.52M
Interest income 163.09M 157.51M 107.39M 27.66M 3.49M
Net interest income 159.01M 155.04M 106.48M 23.76M 2.39M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -19.72000M 8.52M
Total revenue 4153.48M 2190.23M 1226.32M 410.75M 497.28M
Total operating expenses 3098.87M 2208.07M 1646.95M 1130.41M 857.17M
Cost of revenue 450.67M 227.29M 117.83M 29.43M -
Total other income expense net 64.98M -52.02100M 9.66M -33.40900M -42.23900M
Discontinued operations - - - - -
Net income from continuing ops 1292.04M 833.04M -295.05300M -709.59400M -408.26500M
Net income applicable to common shares - - - -709.59400M -408.26500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8682.70M 6202.52M 4542.46M 3134.26M 2850.27M
Intangible assets 272.10M 181.44M 125.23M 174.90M 171.68M
Earning assets - - - - -
Other current assets - - - -0.00100M -
Total liab 1359.61M 704.24M 444.95M 320.56M 316.05M
Total stockholder equity 7323.09M 5498.28M 4097.51M 2813.70M 2534.22M
Deferred long term liab - - - - -
Other current liab - - - 6.32M 5.14M
Common stock - - - 6.64M 6.23M
Capital stock 7.35M 7.23M 7.06M 6.64M 6.23M
Retained earnings -279.76900M -1571.80400M -2404.84400M -2109.79100M -1400.19700M
Other liab - - - 9.28M 6.86M
Good will - - - - -
Other assets - - - 128.45M 66.61M
Cash 3491.29M 1499.94M 2048.84M 800.74M 1334.68M
Cash and equivalents - - - - -
Total current liabilities 1320.19M 669.92M 422.99M 302.28M 301.24M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - - 606.97M 465.41M
Property plant equipment - - - 16.23M 15.84M
Total current assets 6899.10M 4883.10M 4123.74M 2774.20M 2542.97M
Long term investments 50.53M 49.70M 47.16M 40.48M 53.17M
Net tangible assets - - - 2638.80M 2362.54M
Short term investments 948.75M 1878.89M 1131.00M 1391.81M 1002.05M
Net receivables 1489.57M 817.71M 417.99M 277.27M 38.22M
Long term debt - - - - -
Inventory 473.53M 407.23M 310.55M 228.35M 109.08M
Accounts payable 554.27M 482.70M 245.56M 188.72M 208.85M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.84M 1.96M 2.42M 1.74M 1.71M
Deferred long term asset charges - - - - -
Non current assets total 1783.59M 1319.42M 418.72M 360.06M 307.30M
Capital lease obligations 47.16M 39.05M 20.00M 12.43M 11.46M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 939.51M -753.94200M 308.21M -370.50600M -228.23900M
Change to liabilities - - - 0.33M -180.47400M
Total cashflows from investing activities - - - -461.18400M -347.07000M
Net borrowings -4.10700M -7.63800M -3.80100M -4.16500M -3.85500M
Total cash from financing activities 233.01M 279.76M 1336.73M 843.76M 1121.34M
Change to operating activities - - - -34.51400M -44.96500M
Net income 1292.04M 792.72M -272.33392M -709.59400M -408.26500M
Change in cash 1902.21M -520.58200M 1224.61M -533.93600M 117.87M
Begin period cash flow 1499.94M 2048.84M 800.74M 1334.68M 1216.80M
End period cash flow 3491.29M 1499.94M 2048.84M 800.74M 1334.68M
Total cash from operating activities 685.19M -82.74700M -420.32700M -862.80700M -606.81200M
Issuance of capital stock 0.00000M 0.00000M 1196.73M 760.95M 1091.33M
Depreciation 28.10M 17.53M 111.31M 103.63M 5.40M
Other cashflows from investing activities - - - 13.14M 2.60M
Dividends paid - - - - -
Change to inventory -98.95200M -95.99600M -83.03000M -119.27700M -83.88000M
Change to account receivables - - - -222.26000M -31.63200M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -0.37100M 0.44M
Change to netincome - - - 118.17M 136.54M
Capital expenditures 111.68M 68.30M 43.81M 0.84M 3.62M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -422.62800M -325.17300M -308.89100M -375.72200M -340.95100M
Stock based compensation 248.08M 235.18M 232.97M 157.03M 179.37M
Other non cash items 31.63M -0.27700M 2.07M - -75.00000M
Free cash flow 573.51M -151.04800M -464.13900M -966.63000M -728.24600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARGNF
argenx SE		 - -% 835.00 45.77 31.25 13.84 7.12 11.38 36.06
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx SE

Laarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB

Key Executives

Name Title Year Born
Ms. Malini Moorthy Gen. Counsel 1970
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MSc CEO & Exec. Director 1972
Prof. Hans de Haard Ir, Ph.D. Co-Founder & Chief Scientific Officer 1960
Mr. Karl Gubitz Chief Financial Officer 1970
Mr. R. Keith Woods Chief Operating Officer 1968
Mr. Arjen Lemmen M.Sc. VP of Corp. Devel. & Strategy 1985
Dr. David L. Lacey M.D. Advisor 1952
Ms. Andria Wilk Global Head of Quality 1974
Mr. Filip Borgions VP & Global Head of Technical Operations NA
Ms. Beth DelGiacco VP and Global Head of Corp. Communications & Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions